Tryptophan-Based Imaging Agents for Major Depressive Disorders
4 affiliations
- 1Department of Radiology, Nemours Children’s Health, Wilmington, DE 19803, USA
- 2Diagnostic & Research PET/MR Center, Nemours Children’s Health, Wilmington, DE 19803, USA
- 3Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA
- 4Department of Psychological and Brain Sciences, University of Delaware, Newark, DE 19716, USA
Abstract
Major depressive disorder (MDD) is one of the most prevalent mental diseases; early intervention and treatment are crucial. Unfortunately, the complexity of this disorder makes timely intervention challenging. A clear understanding of the biochemical mechanisms in depression will benefit the diagnosis, stratification, and treatment of prevalent mental disorders. One chemical pathway that has attracted interest is the kynurenine (KYN) pathway, which plays several complex roles in the human body, including regulating immune and inflammatory responses. Dysregulated tryptophan metabolism is widely involved in neuropsychiatric disorders, including depression. Decreased tryptophan and its metabolites and the imbalance between the neuroprotective and neurotoxic arms of the KYN pathway are consistently found in patients with major depression. Tryptophan-based radiotracers provide valuable information in studying whole-body tryptophan depletion-related depression and antidepressant mechanisms. Understanding the relationship between the peripheral and central KYN pathway and the biological mechanisms underlying the heterogeneous symptoms with functional imaging in depression is a pivotal part of enhancing potential patient stratification, developing effective diagnostic tools for subtypes, guiding personalized drug development, and improving treatment strategies. We review tryptophan-based radiopharmaceuticals in the study of depression. We summarize the key findings, noting both broad consensus and inconsistencies, as well as limitations. Finally, we offer our perspective on the future development of tryptophan radiopharmaceuticals in guiding depression diagnosis, targeted interventions, treatment evaluation, and drug development in these prevalent mental disorders.
Related
- Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders
- The effect of adapted physical activity programs on the regulation of emotions in people suffering from major depressive disorders after hospital discharge : REAPAD study protocol
- Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder
- The molecular and neurochemical basis of altered intrinsic neural timescales in major depressive disorder: a multimodal imaging-transcriptomic investigation of esketamine and sertraline treatment.
- Pupil size-resting state network coupling in major depressive disorder: a longitudinal iTBS study
BibTeX
@article{stauff2026tryptophanbased,
title = {{Tryptophan-Based Imaging Agents for Major Depressive Disorders}},
author = {Erik Stauff and Hanieh Karimi and Xuan Fu and Heidi H. Kecskemethy and Lauren W. Averill and Xuyi Yue},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16111555},
url = {https://www.mdpi.com/2218-273X/16/11/1555},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tryptophan-Based Imaging Agents for Major Depressive Disorders
AU - Erik Stauff
AU - Hanieh Karimi
AU - Xuan Fu
AU - Heidi H. Kecskemethy
AU - Lauren W. Averill
AU - Xuyi Yue
PY - 2026
DA - 2026/10/26
JO - Biomolecules
DO - 10.3390/biom16111555
UR - https://www.mdpi.com/2218-273X/16/11/1555
AB - Major depressive disorder (MDD) is one of the most prevalent mental diseases; early intervention and treatment are crucial. Unfortunately, the complexity of this disorder makes timely intervention challenging. A clear understanding of the biochemical mechanisms in depression will benefit the diagnosis, stratification, and treatment of prevalent mental disorders. One chemical pathway that has attracted interest is the kynurenine (KYN) pathway, which plays several complex roles in the human body, including regulating immune and inflammatory responses. Dysregulated tryptophan metabolism is widely involved in neuropsychiatric disorders, including depression. Decreased tryptophan and its metabolites and the imbalance between the neuroprotective and neurotoxic arms of the KYN pathway are consistently found in patients with major depression. Tryptophan-based radiotracers provide valuable information in studying whole-body tryptophan depletion-related depression and antidepressant mechanisms. Understanding the relationship between the peripheral and central KYN pathway and the biological mechanisms underlying the heterogeneous symptoms with functional imaging in depression is a pivotal part of enhancing potential patient stratification, developing effective diagnostic tools for subtypes, guiding personalized drug development, and improving treatment strategies. We review tryptophan-based radiopharmaceuticals in the study of depression. We summarize the key findings, noting both broad consensus and inconsistencies, as well as limitations. Finally, we offer our perspective on the future development of tryptophan radiopharmaceuticals in guiding depression diagnosis, targeted interventions, treatment evaluation, and drug development in these prevalent mental disorders.
SN - 2218-273X
ER -